To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.
Additional recommended knowledge
Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Remoxipride". A list of authors is available in Wikipedia.|